28957-08-6
Chemical Structure
Lasiokaurin
- CAS No.: 28957-08-6
- Formula:C22H30O7
- Molecular Weight:406.47
IUPAC Name: (1S,4aR,5S,6S,6aR,9S,11aS,11bS,14R)-5,6,14-trihydroxy-4,4-dimethyl-8-methylene-7-oxododecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-1-yl acetate
InChIKey: DJQLJZNVICMJRV-NGPIVHDLSA-N
SMILES: O[C@]1(OC2)[C@]([C@@H]3O)(C4=O)[C@](CC[C@H]3C4=C)([H])[C@]2([C@H](CC5)OC(C)=O)[C@](C5(C)C)([H])[C@@H]1O
Biological Activity: Lasiokaurin is an anticancer agent. Lasiokaurin can be isolated from Rabdosia rubescens (Hemsl.) H. Hara. Lasiokaurin inhibits the function of the PDPK1-AKT axis, with a Kd value of 75.93 μM for PDPK1. Lasiokaurin inhibits mTOR, STAT3, MAPK and NF-κB. Lasiokaurin reduces the mRNA and protein expression levels of PLK1. Lasiokaurin decreases DNA synthesis levels, induces cell Apoptosis, and regulates Autophagy processes. Lasiokaurin inhibits tumor growth in xenograft models. Lasiokaurin can be used in research related to nasopharyngeal carcinoma, triple-negative breast cancer[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lasiokaurin | 99.68% | Lasiokaurin is an anticancer agent. Lasiokaurin can be isolated from Rabdosia rubescens (Hemsl.) H. Hara. Lasiokaurin inhibits the function of the PDPK1-AKT axis, with a Kd value of 75.93 μM for PDPK1. Lasiokaurin inhibits mTOR, STAT3, MAPK and NF-κB. Lasiokaurin reduces the mRNA and protein expression levels of PLK1. Lasiokaurin decreases DNA synthesis levels, induces cell Apoptosis, and regulates Autophagy processes. Lasiokaurin inhibits tumor growth in xenograft models. Lasiokaurin can be used in research related to nasopharyngeal carcinoma, triple-negative breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Pu H, et al. Exploring the in vitro and in vivo anticancer activity of lasiokaurin on nasopharyngeal carcinoma[J]. Pharmacological Research-Modern Chinese Medicine, 2023, 9: 100303.
- [2]. Lin J, et al. In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model. Molecules (Basel, Switzerland). 2023 Nov 22;28(23):7701. [Content Brief]
- [3]. Liu Z, et al. Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis. Journal of Cancer. 2024;15(8):2318-2328. [Content Brief]
- [4]. Huang R, et al. Lasiokaurin suppresses breast cancer growth by blocking autophagic flux and regulating cellular energy homeostasis. Biochemical pharmacology. 2025 Dec;242(Pt 3):117212. [Content Brief]
Keywords
